KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Liabilities (2019 - 2025)

Royalty Pharma's Total Liabilities history spans 7 years, with the latest figure at $9.9 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 25.7% year-over-year to $9.9 billion; the TTM value through Dec 2025 reached $9.9 billion, up 25.7%, while the annual FY2025 figure was $9.9 billion, 25.7% up from the prior year.
  • Total Liabilities for Q4 2025 was $9.9 billion at Royalty Pharma, up from $9.7 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $9.9 billion in Q4 2025 and bottomed at $6.1 billion in Q1 2021.
  • The 5-year median for Total Liabilities is $7.3 billion (2022), against an average of $7.5 billion.
  • The largest annual shift saw Total Liabilities skyrocketed 184.84% in 2021 before it dropped 13.59% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $7.3 billion in 2021, then rose by 0.29% to $7.3 billion in 2022, then decreased by 13.59% to $6.3 billion in 2023, then grew by 25.13% to $7.9 billion in 2024, then grew by 25.7% to $9.9 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Total Liabilities are $9.9 billion (Q4 2025), $9.7 billion (Q3 2025), and $8.8 billion (Q2 2025).